B
ASND icon

Braidwell’s Ascendis Pharma A/S ASND Stock Holding History

Braidwell’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-106,713
Closed -$16.6M – 56
2025
Q1 		$16.6M Buy
+106,713
New +$15.2M 0.58% 45

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Braidwell's ASND Position: Q2 2025 in Review

Braidwell sold out of Ascendis Pharma A/S (ASND) in Q2 2025, closing a stake of 106,713 shares — an estimated $16.6M sold.

Braidwell first reported a position in ASND in Q1 2025 and held it in 1 quarter. The position peaked at $16.6M in Q1 2025. 247 funds tracked by Wall St. Rank hold ASND as of Q2 2025.

  • Braidwell reported no remaining Ascendis Pharma A/S position as of Q2 2025 after selling out during the quarter.
  • Braidwell sold 106,713 Ascendis Pharma A/S shares in Q2 2025, an estimated $16.6M.
  • Braidwell first reported a position in Ascendis Pharma A/S in Q1 2025 and held it in 1 quarter.
  • Braidwell's Ascendis Pharma A/S position peaked at $16.6M in Q1 2025.
  • 247 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2025.

Based on Braidwell's 13F filing for Q2 2025, filed 14 Aug 2025.